Pharmafile Logo
Pharmafocus logo
Advanced Search

Bristol-Myers Squibb

Showing 11 posts of 146 posts found.

Blood clot fears halt cancer trial enrolment

February 3, 2011
Research and Development BMS, Bristol-Myers Squibb, Eli Lilly, NSCLC, lilly, necitumumab, non small cell lung cancer, non-small cell lung cancer

Lilly and BMS have stopped enrolment in a phase III trial of necitumumab, a new treatment for non-small cell lung …

News

NICE decides to back Abilify in schizophrenia

January 27, 2011
Sales and Marketing Abilify, BMS, Bristol-Myers Squibb, NICE, Otsuka, aripiprazole, schizophrenia

NICE has changed its mind over Bristol-Myers Squibb’s and Otsuka Pharmaceuticals Abilify, deciding to recommend the drug as a schizophrenia …

News

BMS and Sanofi recall 64 million Avalide tablets

January 18, 2011
Manufacturing and Production Avalide, Avapro, Bristol-Myers Squibb, GMP, Good Manufacturing Practice, Sanofi-Aventis, hypertension, irbesartan

Bristol-Myers Squibb and Sanofi-Aventis have started another massive recall of their antihypertensive product Avalide because a manufacturing defect could affect …

News
bristol-myers_squibb_dr_veronique_walsh

BMS appoints Dr Veronique Walsh

January 5, 2011
Sales and Marketing BMS, Bristol-Myers Squibb, Dr Véronique Walsh, appointment, sales and marketing

Bristol-Myers Squibb UK has appointed Dr Véronique Walsh as business unit director, neuroscience and immunoscience . She joins the company …

Appointment

VTE trial boost for Pfizer and BMS’ apixaban

December 31, 2010
Research and Development, Sales and Marketing BMS, Bristol-Myers Squibb, Pfizer, VTE, apixaban, enoxaparin, venous thromboembolism

Pfizer and Bristol-Myers Squibb’s oral anticoagulant apixaban has shown benefits over a standard injectable treatment for venous thromboembolism in a …

News

BMS licences phase II HIV compound festinavir

December 22, 2010
Research and Development BMS, Bristol-Myers Squibb, HIV, NRTI, Oncolys BioPharma, festinavir, nucleoside reverse transcriptase inhibitor

Bristol-Myers Squibb is to pay hundreds of millions of dollars to a Japanese biotech firm to get its hands on …

News

Bristol-Myers Squibb appoints new UK general manager

December 13, 2010
Manufacturing and Production, Research and Development, Sales and Marketing Amadou Diarra, BMS, Bristol-Myers Squibb, appointment, recruitment, sales and marketing

Bristol-Myers Squibb has appointed Amadou Diarra as general manager of its UK company, where he will be in charge of …

News

NICE limits access to cancer drugs, study confirms

November 10, 2010
Sales and Marketing BMS, Bristol-Myers Squibb, Cancer, Cancer Drugs Fund, IPSOR, Maximilian Lebmeier, NICE, hta

NICE became more restrictive in its assessment of new cancer drugs between 2007 and 2009, a new report suggests. The …

News
Advanced melanoma

BMS skin cancer drug hits US regulatory delay

November 3, 2010
Research and Development BMS, Bristol-Myers Squibb, FDA, MDX010-020 trial, ipilimumab, skin cancer

US regulators have announced they need more time to assess Bristol-Myers Squibb’s skin cancer treatment ipilimumab. The FDA will not …

News

BMS faces approval block unless GMP issues are resolved

November 2, 2010
Manufacturing and Production BMS, Bristol-Myers Squibb, FDA, Puerto Rico, belatacept, manufacturing compliance, pharma manufacturing

Bristol-Myers Squibb has been threatened with a block on approvals of certain new drugs, including a biologic for preventing organ …

News

Pharma manufacturing news in brief

October 26, 2010
Manufacturing and Production AMRI, BASF, BMS, Bend Research, Bristol-Myers Squibb, Parmetics, Stirling Pharma, Vical, pharma manufacturing

This week’s round-up of pharmaceutical manufacturing news features updates from Pharmetics, AMRI, Bend Research/BMS, Stirling Pharma, Vical and BASF. A …

News

Latest content

FDA accepts new drug application for Orexo’s opioid overdose medication

November 28, 2023

Arcturus Therapeutics gains FDA ODD for cystic fibrosis treatment

November 28, 2023

Sanofi and Regeneron share results from phase 3 trial for Dupixent as COPD treatment

November 27, 2023

GSK shares results from phase 3 trial for Blenrep as multiple myeloma treatment

November 27, 2023

Alladapt Immunotherapeutics gains FDA Fast Track Designation for ADP101 as food allergy treatment

November 24, 2023